Divi's LaboratoriesNSE:DIVISLAB +0.10%93 Net Margin % is 26.53% as of Mar. 2026, which is 5% above its 10-year median of 25.17. GuruFocus rates NSE:DIVISLAB with a GF Score™ of 93/100 and a GF Value™ of ₹6,729.63 (Fairly Valued). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Divi's Laboratories ranks better than 91.63% on this metric.
The historical rank and industry rank for Divi's Laboratories's Net Margin % or its related term are showing as below:
NSE:DIVISLAB'
s Net Margin % Range Over the Past 10 Years
Min: 20.52 Med: 25.17 Max: 33.64
Current: 24.32
NSE:DIVISLAB's Net Margin % is ranked better than 91.63% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:DIVISLAB: 24.32
Divi's Laboratories (NSE:DIVISLAB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Divi's Laboratories Net Margin % Related Terms
Divi's Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for Divi's Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Divi's Laboratories Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where Divi's Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Divi's Laboratories (NSE:DIVISLAB) has a Net Margin % of 26.53% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Divi's Laboratories and its competitors. This is near median its historical median of 25.17. Over the past decade, Divi's Laboratories' Net Margin % has ranged from 20.52 to 33.64. According to the industry distribution chart, Divi's Laboratories ranks #80 out of 956 companies in the Drug Manufacturers industry, placing it in the top 8.4%.
Is Divi's Laboratories' Net Margin % too high?
Divi's Laboratories' current Net Margin % of 26.53% is near median its 10-year median of 25.17. Over the past 10 years, this metric has ranged from a low of 20.52 to a high of 33.64. The Drug Manufacturers industry median Net Margin % is 5.56. Divi's Laboratories' value of 26.53% is 377.2% above this industry median. Based on the distribution chart, Divi's Laboratories ranks #80 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Divi's Laboratories has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Divi's Laboratories' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Divi's Laboratories ranks #80 out of 956 companies for Net Margin %. This places Divi's Laboratories in the top 8% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Divi's Laboratories' value of 26.53% is 377.2% above this benchmark. Historically, Divi's Laboratories' own Net Margin % has ranged from 20.52 to 33.64 over the past decade. While the company's 10-year median is 25.17 vs. the industry median of 5.56, Divi's Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Divi's Laboratories's current Net Margin % of 26.53% is 377.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Divi's Laboratories and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Divi's Laboratories's current Net Margin % is 26.53%, which is near median its own 10-year median of 25.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Divi's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Divi's Laboratories (NSE:DIVISLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,729.63, compared to a current price of ₹6,753.50 — trading 0.4% above its estimated fair value. The current Net Margin % is 26.53%, which is near median its 10-year median of 25.17 and 377.2% above the Drug Manufacturers industry median of 5.56. Divi's Laboratories' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Divi's Laboratories (NSE:DIVISLAB), the current Net Margin % is 26.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued.
The current stock price of ₹6,753.50 is trading 0.4% above its estimated GF Value™ of ₹6,729.63.
GuruFocus considers Divi's Laboratories to be Fairly Valued.
Key valuation signals for NSE:DIVISLAB:
Net Margin %: 26.53% (near median its 10-year median of 25.17)
GF Value™: ₹6,729.63 vs. price of ₹6,753.50 (0.4% above fair value)
Industry Position: 377.2% above the Drug Manufacturers median (#80 of 956)
No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
93GF Score
Get the complete analysis for NSE:DIVISLAB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DIVISLAB has been successfully added to your 
